Thompson LL, Krasnow NA, Chang MS, et al. - This study sought to define patterns of cutaneous immune-related adverse events (cirAEs) and immune-related adverse events (irAEs) across care settings and explore relationships between the features of the first cirAE, overall irAE risk, and risk of specific irAE subtypes. Researchers performed a retrospective cohort study at a single academic medical center including a total of 358 patients with cancer who initiated anti–programmed death 1/ligand 1 and/or anticytotoxic-T-lymphocyte-4 ICI therapy between January 1, 2016, and March 8, 2019, and developed 1 or more cirAEs, distinguished using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and confirmed via manual medical record review. They included all relevant information documented before March 31, 2020. The data demonstrate the risk of multisystem toxic effects in patients experiencing cirAEs and highlight potential opportunities for dermatologists in the management of noncutaneous toxic effects in this cohort study.